TRAXENS
Traxens, a company providing high-value data and services for the supply chain industry, today announces it has equipped the smart reefer containers of a leading Indoniesian NVOCC company, PT TKSolusindo, with its patented Traxens solution.
PT TKSolusindo is a major Non-Vessel Operating Common Carrier (NVOCC) in Indonesia, a country made up of 17,000 islands, where domestic container trades are essential in the daily life of inhabitants. The containers, delivered from the Taicang and Qingdao factories of China International Marine Containers (CIMC), were equipped with Traxens’ smart solutions in only a few days. These now bring PT TKSolusindo, and its clients, full visibility of shipped cargo in the controlled-atmosphere containers throughout all logistical legs of the journey.
Traxens’ solution addresses key challenges in the shipping industry faced by both asset owners and cargo owners. With the support of telematics, asset owners can control costs and develop more agile business problem solving, while cargo owners can easily keep track of their containers, bringing improved business processes and decision making capabilities. Reduced operational costs, improved supply chain efficiency, enhanced security and the opportunity to extend offerings to customers are amongst the key benefits gained through Traxens’ smart solutions. The whole shipping ecosystem, including ports, freight forwarders, insurance and financial institutions, can also benefit from the value-added data gathered by Traxens’ cutting-edge technology.
Traxens offers a comprehensive solution for the reefer industry, which comprises the company’s Reefer Fleet Management and Reefer Door-to-door Monitoring cloud-based applications via the Traxens-Hub, which collects data from Traxens-Box devices installed on containers.
“Traxens’s novel technology is a great addition to the services we provide to our customers, who are keen on staying informed about their cargo’s whereabouts and conditions at all times,” said Glenn Manoppo from PT TKSolusindo. “The reasonable and competitive pricing offered by Traxens were important in our decision when selecting the right partner for the digital transformation of our operations.”
“We are delighted that our reefer tracking technology was chosen by PT. TKSolusindo and we believe that our solution will support the company with the digital transformation of its shipping business,” said Jacques Delort, managing director of Traxens. “We look forward to further co-operations in Asia, a region where domestic and international shipping is crucial for economic success.”
Traxens counts major BCOs among its customers; it also partners with major shipping lines in providing bespoke tracking data for containers.
About PT Trans Kontainer Solusindo (TKSolusindo)
PT TKSolusindo is a subsidiary of an Integrated Cold Chain Solution Company of PT. Kiat Ananda Group, who became the first integrated services provider for refrigerated goods in Indonesia.
PT TKSolusindo specializes in domestic inter-island transport using reefer containers to reach other areas in Indonesia to distribute customers’s goods. The company was set up in 2014, and is now the largest NVOCC in Indonesia with major customers, including international brands such as Unilever, Pizza Hut, Starbucks, Yakult Probiotic, Kentucky Fried Chicken, Greenfield Diary, etc. and local brands such as Hypermart Retail, Hero Retail, Transmart Retail, Charoen Pokphand Indonesia etc. PT TKSolusindo manages more than 500 fleets, generators and trucking.
PT TKSolusindo will develop its international forwarding to support the group trading business in the future.
ABOUT TRAXENS
Traxens generates, collects, consolidates, enriches and transforms logistics asset data into actionable insight for its clients in the maritime, rail and supply chain industries.
The company’s breakthrough Internet-of-Big-Things technology provides comprehensive, real-time information for managing logistics assets anywhere in the world. Traxens’ solutions digitally transform multi-modal supply chains, enabling customers to reduce costs, optimize investments, comply with environmental regulations and deliver premium services to their customers. Traxens’ IoT solution received the Frost & Sullivan’s Technology Leadership Award in 2019.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190611005054/en/
Contact:
PRESS CONTACT : Géraldine Saunière DIRECTOR OF COMMUNICATIONS Mail: g.sauniere@traxens.com Tel: +33 695 915 899
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom